Zhou Xin-Da, Tang Zhao-You, Ma Zeng-Chen, Wu Zhi-Quan, Fan Jia, Qin Lun-Xiu, Zhang Bo-Heng
The Liver Cancer Institute, Zhong Shan Hospital, Fudan University, 136 Yi Xue Yuan Road, 200032, Shanghai, China.
J Cancer Res Clin Oncol. 2003 Sep;129(9):543-8. doi: 10.1007/s00432-003-0446-6. Epub 2003 Jul 30.
Large primary liver cancer (PLC) more than 10 cm in diameter is not infrequently encountered in clinical practice. This study evaluated the clinicopathological features and long-term results after surgery for large PLC.
Comparison of clinicopathological data between patients with PLC >/=10 cm ( n=1,227) and PLC <10 cm ( n=2,349) during the same period.
In comparison with patients with PLC <10 cm, patients with PLC >/=10 cm were significantly younger ( P<0.01), had a lower incidence of asymptomatic tumors (9.1% vs 39.5%, P<0.001), higher alpha-fetoprotein levels ( >400 ng/ml, 78.3% vs 49.2%, P<0.001), higher gamma-glutamyl transpeptidase levels ( >6U, 87.7% vs 70.5%, P<0.001), a lower incidence of a history of hepatitis (45.0% vs 61.4%, P<0.001) and associated macronodular cirrhosis (cirrhotic nodules >/=0.3 cm, 59.8% vs 66.6%, P<0.001), poor differentiation of tumor cells (Edmondson grade 3-4, 24.3% vs 19.7%, P<0.01), a lower percentage of single nodule tumors (59.9% vs 75.4%, P<0.001) and well-encapsulated tumors (28.5% vs 62.1%, P<0.001), a higher proportion of tumor emboli in the portal vein (20.5% vs 9.0%, P<0.001), a lower resection rate (50.6% vs 86.8%, P<0.001), a lower curative resection rate (54.8% vs 78.3%, P<0.001), a higher operative mortality rate (4.5% vs 2.3%, P<0.001), and less local resection (52.5% vs 80.2%, P<0.001). The 5- and 10-year survival rates after resection were 26.2% and 17.5%, respectively, for patients with PLC >/=10 cm ( n=621), and 54.3% and 39.5%, respectively, for patients with PLC <10 cm ( n=2039) ( P<0.01).
Large PLC had specific clinicopathological features. Surgery is the first choice of treatment. In selected patients, resection is safe and offers the chance of long-term survival. Large PLC does not exclude the possibility of cure.
临床实践中经常会遇到直径超过10 cm的大型原发性肝癌(PLC)。本研究评估了大型PLC手术后的临床病理特征和长期结果。
比较同期直径≥10 cm(n = 1227)和直径<10 cm(n = 2349)的PLC患者的临床病理数据。
与直径<10 cm的PLC患者相比,直径≥10 cm的PLC患者明显更年轻(P<0.01),无症状肿瘤的发生率更低(9.1%对39.5%,P<0.001),甲胎蛋白水平更高(>400 ng/ml,78.3%对49.2%,P<0.001),γ-谷氨酰转肽酶水平更高(>6U,87.7%对70.5%,P<0.001),肝炎病史的发生率更低(45.0%对61.4%,P<0.001),伴有大结节性肝硬化(肝硬化结节≥0.3 cm,59.8%对66.6%,P<0.001),肿瘤细胞分化差(Edmondson 3-4级,24.3%对19.7%,P<0.01),单结节肿瘤的比例更低(59.9%对75.4%,P<0.001),包膜完整的肿瘤比例更低(28.5%对62.1%,P<0.001),门静脉肿瘤栓子的比例更高(20.5%对9.0%,P<0.001),切除率更低(50.6%对86.8%,P<0.001),根治性切除率更低(54.8%对78.3%,P<0.001),手术死亡率更高(4.5%对2.3%,P<0.001),局部切除更少(52.5%对80.2%,P<0.001)。直径≥10 cm的PLC患者(n = 621)切除术后的5年和10年生存率分别为26.2%和17.5%,直径<10 cm的PLC患者(n = 2039)分别为54.3%和39.5%(P<0.01)。
大型PLC具有特定的临床病理特征。手术是首选治疗方法。在选定的患者中,切除是安全的,并提供长期生存的机会。大型PLC并不排除治愈的可能性。